Back to Solutions

Pharmaceutical Manufacturers

Exposure Intelligence for FDA-Regulated Supply Chains

ApertureRisks helps pharmaceutical and biotech manufacturers map API and excipient sourcing concentration, cold-chain dependencies, and single-source supply against the documentation their quality and regulatory teams must defend.

Key Risk Focus Areas

API Sourcing Concentration

Identify single-country and single-site dependence for active pharmaceutical ingredients, key starting materials, and critical excipients.

Regulated Supply Documentation Gaps

Surface where supplier records fall short of the documentation readiness that FDA-regulated change control and audit responses demand.

Cold Chain and Logistics Integrity

Map temperature-controlled lanes, storage points, and carrier dependencies whose failure can compromise product and trigger supply interruption.

Single-Source Supplier Fragility

Surface sole-supplier materials with long requalification timelines where one site outage becomes a product availability event.

Potential Assessment Outputs

Final deliverables are selected during qualification and confirmed in the accepted scope for one defined exposure question.

API and material concentration risk scoring

Cold-chain and lane exposure summary

Documentation gap register organized for quality review

Executive decision brief

What We Will Need From You

API and key-starting-material supplier list with country of origin

Cold-chain lane and storage locations

Sole-source and single-site supplier list, if available

Supplier quality agreement inventory, if available

Evidence That Strengthens the Baseline

Supplier and site list with country of origin

Material-to-product dependency records

Cold-chain lane and carrier records

Prior supply interruption history, if available

Every Paid Exposure Assessment includes

  • One scoped exposure question
  • Evidence-backed exposure baseline
  • Evidence gap and action register
  • One executive decision brief
  • Five-business-day delivery after intake acceptance

Delivered within five business days after accepted intake, consistent with the standard Paid Exposure Assessment delivery specification.

Ready to See Your Exposure?

Try the free Scenario Sandbox to test the workflow, or start the Paid Exposure Assessment tailored to your operating context.

ApertureRisks supports supply risk visibility and documentation readiness. It does not provide regulatory advice, GxP certification, or FDA compliance determinations.